{
    "relation": [
        [
            "Characteristic",
            "Country of origin",
            "USA",
            "United Kingdom",
            "Germany",
            "India",
            "South Korea",
            "Other",
            "Type of cancer",
            "Breast",
            "Colorectal",
            "Lung",
            "Ovarian",
            "Other",
            "Sample size",
            "< 50 patients",
            "50-150 patients",
            "150-250 patients",
            "250-500 patients",
            "500-1000 patients",
            "> 1000 patients",
            "No of polymorphisms examined",
            "1-3 polymorphisms",
            "> 3 polymorphisms",
            "Type of GST examined",
            "GSTM1 present/null",
            "GSTT1 present/null",
            "GSTP1 Ile105Val",
            "GSTP1 Ala114Val",
            "GSTM3 A*/A* or A*/B* or B*/B*",
            "GSTA1 A*/A* or A*/B* or B*/B*",
            "GSTP1 Thr110Ser",
            "GSTP1 Asp147Tyr",
            "GSTO1 Ala140Asp",
            "GSTO2 Asn142Asp"
        ],
        [
            "No of studies (%)",
            "",
            "21 (26.5)",
            "10 (13)",
            "6 (8)",
            "5 (6)",
            "5 (6)",
            "32 (40.5)",
            "",
            "15 (19)",
            "14 (18)",
            "12 (15)",
            "10 (13)",
            "28 (35)",
            "",
            "6 (7.5)",
            "33 (42)",
            "18 (23)",
            "17 (21.5)",
            "2 (2.5)",
            "3 (3.5)",
            "",
            "39 (49)",
            "40 (51)",
            "",
            "54 (68)",
            "46 (58)",
            "57 (72)",
            "7 (9)",
            "2 (2.5)",
            "1 (1)",
            "1 (1)",
            "1 (1)",
            "1 (1)",
            "1 (1)"
        ]
    ],
    "pageTitle": "Translational Medicine and Reliability of Single-Nucleotide Polymorphism Studies: Can We Believe in SNP Reports or Not?",
    "title": "",
    "url": "http://www.medsci.org/v08p0492.htm",
    "hasHeader": true,
    "headerPosition": "FIRST_ROW",
    "tableType": "RELATION",
    "tableNum": 2,
    "s3Link": "common-crawl/crawl-data/CC-MAIN-2015-32/segments/1438042990900.28/warc/CC-MAIN-20150728002310-00006-ip-10-236-191-2.ec2.internal.warc.gz",
    "recordEndOffset": 575453163,
    "recordOffset": 575428079,
    "tableOrientation": "HORIZONTAL",
    "TableContextTimeStampBeforeTable": "{21576=ISSN 1449-1907, 11479=We electronically searched the PubMed medical literature database and ISI Web of Science from inception to June 1, 2009, without language restrictions, using the following keyword combinations: (glutathione s-transferase OR GST OR GSTT1 OR GSTM1 OR GSTP1) AND (polymorphism OR polymorphisms OR SNP OR mutation) AND (cancer OR malign* OR carcinoma OR tumor OR tumour). The electronic search was supplemented by a manual review of the references of included studies., 21613=4 August 2015}",
    "TableContextTimeStampAfterTable": "{27185=39. Liu B, Wei J, Zou Z, Qian X, Nakamura T, Zhang W, Ding Y, Feng J, Yu L. Polymorphism of XRCC1 predicts overall survival of gastric cancer patients receiving oxaliplatin-based chemotherapy in Chinese population. Eur J Hum Genet. 2007;15:1049-53, 29118=46. Okcu MF, Selvan M, Wang LE, Stout L, Erana R, Airewele G, Adatto P, Hess K, Ali-Osman F, Groves M, Yung AW, Levin VA, Wei Q, Bondy M. Glutathione S-transferase polymorphisms and survival in primary malignant glioma. Clin Cancer Res. 2004Apr15;10(8):2618-25, 35151=64. Kweekel DM, Koopman M, Antonini NF, Van der Straaten T, Nortier JW, Gelderblom H, Punt CJ, Guchelaar HJ. GSTP1 Ile105Val polymorphism correlates with progression-free survival in MCRC patients treated with or without irinotecan: a study of the Dutch Colorectal Cancer Group. Br J Cancer. 2008;99:1316-21, 40470=81. Le Morvan V, Smith D, Laurand A, Brouste V, Bellott R, Soubeyran I, Mathoulin-Pelissier S, Robert J. Determination of ERCC2 Lys751Gln and GSTP1 Ile105Val gene polymorphisms in colorectal cancer patients: relationships with treatment outcome. Pharmacogenomics. 2007;8:1693-703, 21192=19. Csejtei A, Tibold A, Varga Z, Koltai K, Ember A, Orsos Z, Feher G, Horvath OP, Ember I, Kiss I. GSTM, GSTT and p53 polymorphisms as modifiers of clinical outcome in colorectal cancer. Anticancer Res. 2008;28:1917-22, 24037=29. Huang MY, Fang WY, Lee SC, Cheng TL, Wang JY, Lin SR. ERCC2 2251A>C genetic polymorphism was highly correlated with early relapse in high-risk stage II and stage III colorectal cancer patients: a preliminary study. BMC Cancer. 2008;8:50, 20672=17. Chacko P, Joseph T, Mathew BS, Rajan B, Pillai MR. Role of xenobiotic metabolizing gene polymorphisms in breast cancer susceptibility and treatment outcome. Mutat Res. 2005;581:153-63, 20917=18. Chung HH, Kim MK, Kim JW, Park NH, Song YS, Kang SB, Lee HP. XRCC1 R399Q polymorphism is associated with response to platinum-based neoadjuvant chemotherapy in bulky cervical cancer. Gynecol Oncol. 2006;103:1031-7, 41400=84. Par\u00e9 L, Marcuello E, Alt\u00e9s A, del R\u00edo E, Sedano L, Salazar J, Cort\u00e9s A, Barnadas A, Baiget M. Pharmacogenetic prediction of clinical outcome in advanced colorectal cancer patients receiving oxaliplatin/5-fluorouracil as first-line chemotherapy. Br J Cancer. 2008;99:1050-5, 30809=51. Rajkumar T, Samson M, Rama R, Sridevi V, Mahji U, Swaminathan R, Nancy NK. TGFbeta1 (Leu10Pro), p53 (Arg72Pro) can predict for increased risk for breast cancer in south Indian women and TGFbeta1 Pro (Leu10Pro) allele predicts response to neo-adjuvant chemo-radiotherapy. Breast Cancer Res Treat. 2008;112:81-7, 43226=89. Ruwali M, Pant MC, Shah PP, Mishra BN, Parmar D. Polymorphism in cytochrome P450 2A6 and glutathione S-transferase P1 modifies head and neck cancer risk and treatment outcome. Mutat Res. 2009 In press, 45603=Received 2011-5-29 Accepted 2011-8-9 Published 2011-8-24, 25374=33. Kim EJ, Jeong P, Quan C, Kim J, Bae SC, Yoon SJ, Kang JW, Lee SC, Jun Wee J, Kim WJ. Genotypes of TNF-alpha, VEGF, hOGG1, GSTM1, and GSTT1: useful determinants for clinical outcome of bladder cancer. Urology. 2005;65:70-5, 44275=93. Callaham M, Wears RL, Weber E. Journal prestige, publication bias, and other characteristics associated with citation of published studies in peer-reviewed journals. JAMA. 2002;287(21):2847-2850, 18166=5. Littner Y, Mimouni FB, Dollberg S, Mandel D. Negative results and impact factor: A lesson from neonatology. Arch Pediatr Adolesc Med. 2005;159:1036-1037, 37555=72. Khedhaier A, Remadi S, Corbex M, Ahmed SB, Bouaouina N, Mestiri S, Azaiez R, Helal AN, Chouchane L. Glutathione S-transferases (GSTT1 and GSTM1) gene deletions in Tunisians: susceptibility and prognostic implications in breast carcinoma. Br J Cancer. 2003;89:1502-7, 33526=59. Sanyal S, Ryk C, De Verdier PJ, Steineck G, Larsson P, Onel\u00f6v E, Hemminki K, Kumar R. Polymorphisms in NQO1 and the clinical course of urinary bladder neoplasms. Scand J Urol Nephrol. 2007;41:182-90, 30539=50. Rajagopal R, Deakin M, Fawole AS, Elder JB, Elder J, Smith V, Strange RC, Fryer AA. Glutathione S-transferase T1 polymorphisms are associated with outcome in colorectal cancer. Carcinogenesis. 2005;26:2157-63, 32663=57. Ruzzo A, Graziano F, Kawakami K, Watanabe G, Santini D, Catalano V, Bisonni R, Canestrari E, Ficarelli R, Menichetti ET, Mari D, Testa E, Silva R, Vincenzi B, Giordani P, Cascinu S, Giustini L, Tonini G, Magnani M. Pharmacogenetic profiling and clinical outcome of patients with advanced gastric cancer treated with palliative chemotherapy. J Clin Oncol. 2006;24:1883-91, 42437=87. Goekkurt E, Al-Batran SE, Hartmann JT, Mogck U, Schuch G, Kramer M, Jaeger E, Bokemeyer C, Ehninger G, Stoehlmacher J. Pharmacogenetic analyses of a phase III trial in metastatic gastroesophageal adenocarcinoma with fluorouracil and leucovorin plus either oxaliplatin or cisplatin: a study of the arbeitsgemeinschaft internistische onkologie. J Clin Oncol. 2009;27:2863-73, 24338=30. Huang ZH, Hua D, Du X. Polymorphisms in p53, GSTP1 and XRCC1 predict relapse and survival of gastric cancer patients treated with oxaliplatin-based adjuvant chemotherapy. Cancer Chemother Pharmacol. 2009 In press, 36123=67. Braun MS, Richman SD, Quirke P, Daly C, Adlard JW, Elliott F, Barrett JH, Selby P, Meade AM, Stephens RJ, Parmar MK, Seymour MT. Predictive biomarkers of chemotherapy efficacy in colorectal cancer: results from the UK MRC FOCUS trial. J Clin Oncol. 2008;26:2690-8, 33095=58. Ruzzo A, Graziano F, Loupakis F, Rulli E, Canestrari E, Santini D, Catalano V, Ficarelli R, Maltese P, Bisonni R, Masi G, Schiavon G, Giordani P, Giustini L, Falcone A, Tonini G, Silva R, Mattioli R, Floriani I, Magnani M. Pharmacogenetic profiling in patients with advanced colorectal cancer treated with first-line FOLFOX-4 chemotherapy. J Clin Oncol. 2007;25:1247-54, 32426=56. Rigual NR, Anderson GR, Loree TR, Wiseman S, Alrawi S, Stoler DL. Molecular prognosticators and genomic instability in papillary thyroid cancer. Laryngoscope. 2005;115:1479-85, 19553=13. Agalliu I, Lin DW, Salinas CA, Feng Z, Stanford JL. Polymorphisms in the glutathione S-transferase M1, T1, and P1 genes and prostate cancer prognosis. Prostate. 2006;66:1535-41, 44531=94. Tan NC, Mulley JC, Berkovic SF. Genetic association studies in epilepsy: \"the truth is out there\". Epilepsia. 2004Nov;45(11):1429-42}",
    "textBeforeTable": "Characteristics of eligible genetic association studies \u00a0Table 1\u00a0 A total of 79 articles that fulfilled the inclusion criteria were found [13-91]. A total of 10 GST polymorphisms were analysed: GSTM1, GSTP1 Ile105Val, GSTP1 Ala114Val, GSTP1 Thr110Ser, GSTP1 Asp147Tyr, GSTT1, GSTM3, GSTA1, GSTO1, GSTO2. Of those, 39 examined 1-3 polymorphisms [13,14,16,19,20,23,24,26-28,31,36,37,39-41,45,46,48,50,53,56,60-62,64,65,68,69,72-74,76-79,81,89,91] and 40 more than 3 polymorphisms [15,17,18,21,22,25,29,30,32-35,38,42-44,47,49,51,52,54,55,57-59,63,66,67,70,71,75,80,82-88,90]. Fifty four studies examined the GSTM1 polymorphism [13,14,16,17,19-27,30-33,35,37,38,43-46,48,49,51-63,65,68,69,70,72-75,77,78,82,83,85-87], 57 the GSTP1 Ile105Val polymorphism [13-16,18,21,22,26,28-30,32-49,51-55,57-61,64,66,67,71,74,76-85,87-90], 46 the GSTT1 polymorphism [13,14,16,17,19, 21-23,25,27,32,33,35,37,38,43-46,48-63,65,70,72,74,75,77,78,82,83,85,87]. Only a small number of reports were available for other polymorphisms: GSTP1 Ala114Val (n=7) [15,32,40,42,66,80,85],",
    "textAfterTable": "\u00a0Table 2\u00a0 Outcome of eligible studies (positive-negative) according to number of polymorphisms tested Polymorphisms No of studies (%) P-value Positive outcome (%) Negative outcome (%) any GST analysed 1-3 polymorphisms tested 29 (74) 10 (26) 0.004 > 3 polymorphisms tested 17 (42.5) 23 (57.5) GSTM1 present/null 1-3 polymorphisms tested 13 (48) 14 (52) 0.001 > 3 polymorphisms tested 2 (7) 25 (93) GSTT1 present/null 1-3 polymorphisms tested 4 (19) 17 (81) 0.685 > 3 polymorphisms tested 6 (24) 19 (76) GSTP1 Ile105Val 1-3 polymorphisms tested > 3 polymorphisms tested 11 (46) 9 (27) 13 (54) 24 (73) 0.147 GSTP1 Ala114Val 1-3 polymorphisms tested 1 (100) 0 (0) 0.286 > 3 polymorphisms tested 1 (17) 5 (83) \u00a0Table 3\u00a0 Impact factor and Citations per Year in studies regarding outcome and number of polymorphisms Impact Factor Citations Per Year Mean (+/- SD) Median (range) P-value Mean +/- SD Median (range) P-value Any GST tested",
    "hasKeyColumn": true,
    "keyColumnIndex": 0,
    "headerRowIndex": 0
}